Speech-Language Pathologists in North Potomac, MD Accepting Medicare
7 Speech-Language Pathologists found. Showing 1 - 7
 Fatemeh Soltanmohammadi Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 12516 Shoemaker Way, North Potomac, MD 20878 Phone: 240-855-5202 |
 Peter Kenneth Stoll Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 10810 Darnestown Rd Ste 102, North Potomac, MD 20878 Phone: 240-200-5305 |
Samantha Schreiber, MS ED CF-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 10810 Darnestown Rd Ste 102, North Potomac, MD 20878 Phone: 914-643-5234 |
Mrs. Emily G Bressler, M.S.,CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 11218 Welland St, North Potomac, MD 20878 Phone: 310-762-5557 Fax: 301-762-6674 |
Neda Ghandchi Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 17701 Stoneridge Dr, North Potomac, MD 20878 Phone: 240-603-6976 |
Jennifer Coon, M.A. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 15001 Dufief Dr, North Potomac, MD 20878 Phone: 012-279-4980 |
 Regnell Rehab Llc Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 14643 Devereaux Ter, North Potomac, MD 20878 Phone: 240-778-5332 Fax: 240-238-2620 |
News Archive
New guidance on making complex decisions about injured athlete's return to play
When is it appropriate for an injured athlete to return to competition? A new three-step framework provides team physicians and other sport medicine clinicians with guidance on making complex decisions about return to play, reported in the September Clinical Journal of Sport Medicine.
Infants with flat head syndrome may be at increased risk of developmental delays, study finds
Babies with flat head syndrome may be at heightened risk of developmental delays, a new study has found.
$58M INext Fund established to encourage investment in Indiana life sciences opportunities
Capitalizing on the continued strong growth of Indiana's life sciences industry and an active venture capital market, leaders from BioCrossroads, Eli Lilly and Company, Indiana State Teachers Retirement Fund, Indiana University, Purdue University, the University of Notre Dame, Richard M. Fairbanks Foundation, and Credit Suisse today announced the establishment of the INext Fund, a $58 million venture capital fund of funds.
Pharmaxis, Synairgen partner to develop LOXL2 inhibitor to treat idiopathic pulmonary fibrosis
Australian pharmaceutical company Pharmaxis Ltd and UK biotechnology company Synairgen plc today announced they have entered into a research collaboration to develop a selective inhibitor to the lysyl oxidase type 2 enzyme (LOXL2) to treat the fatal lung disease idiopathic pulmonary fibrosis (IPF).
› Verified 1 days ago
Speech-Language Pathologists
Physical Therapists
Podiatrists
Occupational Therapists
Audiologists